Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by Ciaoon Dec 15, 2023 9:58am
84 Views
Post# 35786497

RE:Proph. the manipulator

RE:Proph. the manipulator
fossi_2002 wrote:
Comment by prophetoffactzon Dec 15, 2023 3:57am
lscfa wrote: Nov 13, 2023 — HC Wainwright Cuts Aeterna Zentaris' Price Target to $15 From $28, Maintains Buy Rating
With 4.86 million shares according to Stockhouse US$28 would be a US$138 million market cap. That is similar to what Novo Nordisk put into AEZS's growth hormone deficiency test:

...US$145 million plus tiered royalties and an equity investment worth more than US$36
million...

Proph... is the biggest manipulator on this board. If Wainwright cuts the price target from 28$ to 15$, the market value is just under 73 million, but he talks about 138 million because he simply uses the old price target - it couldn't be worse!


HC Wainwright is biased as they did the last underwriting with shares at $1.45. Given the 25 for 1 share rollback, it was effectively at $36.25. Shares are at $2.18 for a loss of 96% all in a matter of 3 years.

AEZS is a dog, period. 

Until recently, CZO had a very high gross margin de-risked base businses, was generating net profit, had positive cash flow, and adding to its cash to fund it's pipeline with no share dilution over the past 7 years. Hey we just had a "bump" in the road due to the spinoff of Kenvue and re-ordering should normalize soon. Why the panic to merge with a dog like AEZS? A dog is a dog, a NASDAQ listing doesn't hide the fact. After the last financing by AEZS 3 years ago the share price has dropped 96%. And yes, Gagnon rejoined the board on January 1, 2020 to guide them. What a disaster. Why would CZO want any part of this. Vote NO to the merger.


<< Previous
Bullboard Posts
Next >>